Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIVERSITY: Dabigatran vs Standard of Care for Pediatric VTE
NCT01895777Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2013
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial of dabigatran etexilate oral solution in venous thromboembolism (VTE) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Composite of Complete Thrombus Resolution, Freedom From Recurrent VTE, and Freedom From VTE-related Mortality at 12 weeks. Started Sep 2013; status: completed.
02
Drugs
dabigatran etexilate oral solution
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT01895777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01895777.